NANOVIRICIDES, INC. Stock Compensation Disclosure
Note 9 – Common Stock Warrants
Stock Warrants
Weighted | Weighted | |||||||||
Average | Average | |||||||||
Number of | Exercise | Remaining | Aggregate | |||||||
| Shares |
| Price |
| Contractual life |
| Intrinsic | |||
Outstanding and exercisable at July 1, 2023 |
| 8,004 | $ | 4.96 | — |
| $ | 238 | ||
Granted |
| 1,144 | 1.76 | 3.50 |
|
| — | |||
Exercised |
| — |
| — |
| — |
|
| — | |
Expired |
| 2,286 |
| 5.26 |
| — |
|
| — | |
Canceled |
| — |
| — |
| — |
|
| — | |
Outstanding and exercisable at June 30, 2024 |
| 6,862 | $ | 3.64 | 1.67 |
| $ | 399 | ||
Granted |
| 1,144 | 1.79 | 3.50 |
|
| — | |||
Exercised |
| — |
| — |
| — |
|
| — | |
Expired |
| 2,286 |
| 5.26 |
| — |
|
| — | |
Canceled |
| — |
| — |
| — |
|
| — | |
Outstanding and exercisable at June 30, 2025 |
| 5,720 | $ | 2.62 | 1.70 |
| $ | 4 | ||
Of the above warrants; 2,288 expire in fiscal year ending June 30, 2026; 1,144 expire in fiscal year ending June 30, 2027; 1,144 expire in fiscal year ending June 30, 2028 and 1,144 expire in fiscal year ending June 30, 2029.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Sep 29, 2025 | Showing above |
| 2024 | Sep 27, 2024 | |
| 2023 | Oct 13, 2023 | |
About Stock Compensation Disclosures
Stock-based compensation disclosures detail the equity awards granted to employees and executives — including stock options, restricted stock units (RSUs), and performance shares — along with the valuation methods and assumptions used to expense them. This section reveals the true cost of talent retention and the alignment between management incentives and shareholder interests.
Key signals: total unrecognized compensation expense and its expected recognition period signal future earnings headwinds from already-granted awards. For stock options, examine Black-Scholes assumptions — expected volatility, risk-free rate, and expected term — as understating any of these reduces reported compensation expense. Compare stock compensation expense as a percentage of revenue against peers to assess dilution cost. Watch vesting schedules for acceleration clauses tied to change-of-control events. Performance-based awards with undemanding targets may indicate weak governance. Add back stock compensation to operating cash flow to calculate a more conservative free cash flow figure.